What Is ARA-290 (Cibinetide)? A Research Guide

ARA-290 is a synthetic peptide eleven amino acids in length, produced through solid-phase peptide synthesis. Its sequence is derived from the helical B domain of erythropoietin, a small structural region of the parent hormone rather than the full protein. As a research compound it is supplied as a lyophilized (freeze-dried) powder that is reconstituted before use, following the same general handling principles used for other research peptides.

The defining feature of ARA-290 is that it was engineered, not simply isolated. Investigators built the peptide to reproduce EPO's interaction with a specific receptor complex while leaving out the parts of the parent molecule responsible for stimulating the bone marrow. This design intent is what separates cibinetide from erythropoietin itself in the research literature.

Erythropoietin has two distinct actions described in the literature: it binds the classical erythropoietin receptor (EPOR), a homodimer that drives red blood cell production, and it also engages a separate signaling complex referred to as the innate repair receptor (IRR), a heteromer involving the beta-common receptor subunit that has been associated in preclinical models with cellular protection and repair signaling rather than blood formation.

ARA-290 is described in the research literature as engineered to selectively engage the innate repair receptor while lacking meaningful activity at the classical EPO receptor. Because of this selectivity, preclinical characterization studies report that ARA-290 does not reproduce the hematopoietic, or blood-cell-stimulating, activity associated with EPO. Researchers studying the compound treat this receptor-selectivity profile as its central distinguishing property relative to the parent hormone.

This mechanistic distinction is why ARA-290 is studied as a separate research entity from erythropoietin, even though the two molecules share a common origin. Any research use of ARA-290 should account for this selective receptor engagement when interpreting model outcomes.

In the published literature, ARA-290 has been examined across a range of preclinical models related to tissue protection and inflammation, including cellular and animal models exploring how innate repair receptor signaling relates to inflammatory processes and stress responses in tissue systems.

The compound has also appeared in research focused on small-fiber neuropathy, including work examining neuropathic pain associated with sarcoidosis, an inflammatory condition, as well as in metabolic stress research models. These investigations are preclinical and mechanistic in nature, characterizing how the compound behaves in specific model systems rather than establishing any outcome relevant to human patients.

As with any research compound, findings from cell-based and animal-model studies are experimental and do not establish that ARA-290 produces any particular effect in humans. This article summarizes categories of published research; it does not endorse or restate specific results as clinical fact.

Cibinetide is distinct among many research peptides in that it has been studied in human clinical trials in addition to preclinical models. This is a documented part of its research history and does not change the regulatory or intended-use status of the material sold by Optimum ReGen Peptides.

ARA-290 is not an approved drug. It has not received marketing approval for any human indication, and its presence in clinical-trial literature does not make research-use material approved, safe, or intended for human administration. The peptide sold here is manufactured and distributed strictly for laboratory research, is not clinical-grade or trial-grade material, and carries no dosing, treatment, or efficacy claims of any kind.

Researchers evaluating ARA-290 should treat clinical-trial publications the same way they treat any other secondary literature: as context for the compound's research history, not as authorization or guidance for administering the research-use material sold here to humans or animals.

For any research compound, the quality of the material determines the quality of the data it produces. A batch-level certificate of analysis (COA) documents HPLC purity and mass-spectrometry identity for the specific lot, confirming both that the material is the intended peptide and how much of the sample consists of that peptide versus residual synthesis impurities.

Optimum ReGen Peptides supplies ARA-290 for laboratory research with third-party batch testing and a published COA, compounded in the United States by a licensed 503A pharmacy. Researchers should verify the COA for the specific lot they receive before beginning work.